Autolus Therapeutics’ Obe-Cel’s Shows Compelling Safety Over Gilead’s Drug For Acute Lymphoblastic Leukemia
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9
How Is The Market Feeling About Gilead Sciences?
Gilead Sciences’s (NYSE:GILD) short percent of float has risen 6.96% since its last report. The company recently reported…
Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation
Gilead Sciences Inc's (NASDAQ: GILD) Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by lower Veklury (remdesivir) sales.
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of ‘Perfectly Normal’ 5% Pullback This Month
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost.
European Commission Approves Gilead’s Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer
-- Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the TROPiCS-02 Study in Pre-Treated HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH–) Metastatic Breast Cancer vs. Physician's Choice
Gilead Sciences, Inc. Presented New Data Reinforcing The Efficacy, Safety, And Tolerability Profile Of Lenacapavir Taken Twice-Yearly, Demonstrated Sustained Impact On Health-Related Quality Of Life In People With HIV
– Patient-Reported Outcomes From the CAPELLA Trial Align With the Demonstrated Safety and Tolerability Profile of Lenacapavir –
– Analyses Show Oral Bridging Maintains Virologic Suppression When
Trial Setback For Gilead Sciences: Shuts Late-Stage Magrolimab/Azacitidine Combo Study In Type Of Blood Cancer
Gilead Sciences Inc (NASDAQ: GILD) decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility
Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades.
Expert Ratings for Gilead Sciences
Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…